Compugen (CGEN) Stock News, Mar-Jul 2025

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced upcoming presentations of its AI/ML-driven predictive computational research at two major scientific conferences. The first presentation will be at the 2025 Annual Congress of the European Association for Cancer Research in Lisbon, Portugal (June 16-19), focusing on predicting immune evasion and immunotherapy resistance in TNBC subtypes. The second presentation will take place at the International Society for Computational Biology conference in Liverpool, UK (July 20-24), addressing computational prediction of TNBC tumor subtypes using single cell atlas analysis. Both presentations highlight Compugen's expertise in using computational methods to understand complex cancer biology. The posters will be made available on Compugen's website after the presentations.

AstraZeneca and Daiichi Sankyo have initiated the DESTINY-Endometrial01 phase 3 trial for ENHERTU in first-line treatment of HER2 expressing primary advanced or recurrent endometrial cancer. The study will evaluate ENHERTU combined with rilvegostomig or pembrolizumab versus standard platinum-based chemotherapy with pembrolizumab. The trial targets patients with HER2 expressing (IHC 3+/2+), mismatch repair proficient endometrial cancer, a condition affecting 18-56% of cases with a median survival of up to 30 months in advanced stages. This initiative follows positive results from the DESTINY-PanTumor02 study, which led to tumor agnostic approval for ENHERTU in previously treated HER2 positive metastatic tumors. The trial represents a significant step in addressing the unmet need in endometrial cancer treatment, where no HER2 directed medicines are currently approved for first-line therapy.

AstraZeneca and Daiichi Sankyo reported promising results for DATROWAY (datopotamab deruxtecan) in treating non-small cell lung cancer (NSCLC) across three clinical trials presented at ASCO 2025. In TROPION-Lung02, the combination of DATROWAY with pembrolizumab showed a 54.8% objective response rate in the doublet arm and 55.6% in the triplet arm including chemotherapy. TROPION-Lung04 demonstrated a 57.5% response rate when combining DATROWAY with rilvegostomig. The NeoCOAST-2 trial showed encouraging results in early-stage NSCLC with a 35.2% pathologic complete response rate when combining DATROWAY with durvalumab and chemotherapy. Safety profiles were consistent with previous studies, with manageable adverse events including some cases of interstitial lung disease.

Compugen (NASDAQ: CGEN) reported its Q1 2025 financial results and corporate updates. The company initiated a platform trial of COM701 maintenance therapy for platinum-sensitive ovarian cancer patients and continues recruitment for GS-0321 Phase 1 trial. Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across various cancers. Financially, Compugen reported $103.7 million in cash with runway into 2027, $2.3 million in revenues, and a net loss of $7.2 million ($0.08 per share) for Q1 2025. The company announced key leadership changes effective September 2025, with current CEO Dr. Anat Cohen-Dayag becoming Executive Chair and CSO Dr. Eran Ophir assuming the CEO position.

Compugen (NASDAQ: CGEN) announced key leadership changes effective September 2025. Dr. Anat Cohen-Dayag, current President and CEO, will transition to Executive Chair of the Board of Directors, while Dr. Eran Ophir, current Chief Scientific Officer, will become President and CEO. Paul Sekhri will step down as Board Chair after 8 years. Under Dr. Cohen-Dayag's leadership since 2010, Compugen transformed into a therapeutic discovery company with an immuno-oncology pipeline powered by Unigen™, their AI/ML platform. The company's portfolio includes COM701, COM902, and partnerships with AstraZeneca and Gilead. Dr. Cohen-Dayag will focus on corporate strategy and strategic collaborations in her new role, while Dr. Ophir brings nearly a decade of experience at Compugen and has been instrumental in building the company's pipeline. The company maintains a strong financial position with cash runway into 2027.

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, has scheduled the release of its first quarter 2025 financial results for Monday, May 19, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET where management will discuss the results and provide a corporate update. Investors can join via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through the company's website. A replay will be available on their website after the live event.

Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, has announced its participation in three major virtual investor conferences in April 2025:

• H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, featuring a fireside chat at 9:30 am ET
• 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat scheduled for 8:00 am ET
• Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, including a fireside chat at 12:00 pm ET

All events will include fireside chats and one-on-one meetings. Live webcasts will be available on Compugen's website investor relations page, with replays accessible after the events.

Compugen (NASDAQ: CGEN) reported its Q4 and full year 2024 results, highlighting significant progress in its cancer immunotherapy pipeline. The company is set to initiate a randomized adaptive platform trial for COM701 maintenance therapy in platinum-sensitive ovarian cancer in Q2 2025. Clinical data from SITC 2024 supports the further development of COM701 as a first-in-class anti-PVRIG antibody.

Financial highlights include a strong cash position of $103.3 million as of December 31, 2024, with runway expected into 2027. The company reported revenues of $27.9 million for 2024, compared to $33.5 million in 2023. Net loss for 2024 was $14.2 million ($0.16 per share), improved from $18.8 million ($0.21 per share) in 2023.

Partner developments include AstraZeneca's expansion of the rilvegostomig program to seven Phase 3 trials, and Gilead's initiation of Phase 1 trials for GS-0321, which triggered a $30 million milestone payment to Compugen in 2024.

Compugen (Nasdaq: CGEN) reported its Q4 and full-year 2024 results, highlighting significant progress in its cancer immunotherapy pipeline. The company presented promising clinical data at SITC 2024 for COM701, their first-in-class anti-PVRIG antibody, and plans to initiate a randomized trial for ovarian cancer treatment in Q2 2025.

Key developments include:

• First patient dosed in Phase 1 trial of GS-0321 (previously COM503) licensed to Gilead
• Partner AstraZeneca expanded rilvegostomig program to seven Phase 3 trials
• Strong financial position with $103.3 million cash balance as of December 31, 2024
• 2024 revenues of $27.9 million compared to $33.5 million in 2023
• Net loss of $14.2 million for 2024, improved from $18.8 million loss in 2023

The company's cash runway is expected to fund operations into 2027, supported by milestone payments from partnerships with AstraZeneca and Gilead.